Public debate around tobacco harm reduction (THR) is increasingly shaped not only by science, but by how that science is communicated. As non-combustible nicotine products expand across global markets, the gap between evidence and public understanding has become a central policy challenge. Miscommunication, oversimplification, and emotive framing risk distorting regulatory discussions at precisely the moment…
Debates around tobacco harm reduction are increasingly shaped not only by emerging products and regulatory decisions, but by how science itself is communicated. A recent commentary on misinformation and “clickbait science” in the tobacco harm reduction space highlights a growing concern: that exaggerated claims, selective interpretation of findings, and sensational headlines can distort both public…
Nicotine pouches remain at the centre of the global harm‑reduction conversation — and a major new peer‑reviewed review helps explain why. A new narrative review by Konstantinos Farsalinos in Internal and Emergency Medicine reinforces a clear message: modern, tobacco‑free nicotine pouches sit at the very lowest end of the toxicant‑exposure continuum. Chemical analyses and biomarker…
Recent commentary describing nicotine pouches as “a wolf in sheep’s clothing” reflects legitimate public-health concerns about youth uptake, long-term uncertainty, and nicotine dependence. However, the framing risks obscuring a critical distinction at the heart of modern tobacco control: the difference between absolute risk and relative risk. Nicotine pouches are not risk-free, but the available evidence…
As nicotine pouches continue to attract regulatory attention, discussion has increasingly focused on isolated clinical observations and precautionary warnings, often without sufficient context on real-world use patterns or comparative risk. This imbalance risks obscuring a more important question for public health: how nicotine pouches are actually used, by whom, and how regulation can address legitimate…
A GINN Insight responding to recent Medscape coverage Nicotine pouches are increasingly positioned at the centre of a familiar policy tension: how to protect young people from nicotine initiation without undermining harm-reduction pathways for adults who smoke. Recent media coverage, including a Medscape Medical News feature, rightly raises youth-protection concerns but risks misrepresenting the evidence…
As nicotine pouches gain visibility in multiple markets, debate around their public-health role is intensifying. A recent peer-reviewed study published in JAMA Network Open adds important empirical clarity to that discussion, particularly around who is using nicotine pouches, why they are using them, and what this means for smoking-related harm. Rather than focusing on speculative…
As nicotine pouches continue to attract regulatory attention, a recurring challenge for policymakers is separating assumptions from evidence. Much of the debate has focused on hypothetical risks, youth narratives, or product novelty, while comparatively less attention has been paid to how adult users actually perceive and use these products in real-world contexts. A recent peer-reviewed…
Following GINN’s recent market‑insights visit to Lebanon, led by our Director Shem Baldeosingh, we continue to learn from frontline experts who see the realities of nicotine use, smoking, and harm reduction every day. This week, Dr Vera Matta (@dr.veramatta), a respected clinician and public health communicator, highlighted an important point while reviewing REBEL White Slim…
As nicotine pouches continue to expand across multiple markets, questions about who uses them, why they are used, and how they fit into tobacco control strategies are becoming increasingly important. A recent peer-reviewed article published by Springer adds to this evidence base by examining patterns of nicotine pouch use and their implications for public health…